Trial intelligence / Profile preview

Zanubrutinib plus rituximab in relapsed/refractory non-GCB DLBCL and indolent lymphomas

CTR20170965Phase 2Completed

Sponsor

BeiGene

Start

Oct 2017

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1